Assessment of Safety of GlaxoSmithKline (GSK) Biologicals' Combined Reduced Antigen Content Diphtheria-tetanus Toxoids and Acellular Pertussis Vaccine (dTPa), Boostrix When Administered According to the Approved Prescribing Information in Korea
Phase of Trial: Phase IV
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 01 Apr 2019 Results published in the Journal of Korean Medical Science
- 21 Apr 2016 Status changed from recruiting to completed.
- 30 Oct 2015 Planned number of patients changed from 600 to 673 as reported by ClinicalTrials.gov record.